# Protocol 1 — Opioid-Free General Anesthesia + PECS/Serratus Blocks

### Post-Mastectomy Breast Implant Revision

**First-Line Preferred Pathway** • Version 2.0 — December 2025

[![License: CC BY 4.0](https://img.shields.io/badge/License-CC%20BY%204.0-lightgrey.svg)](https://creativecommons.org/licenses/by/4.0/)

---

## Educational Use Disclaimer

**This protocol is an educational framework, not an institutional clinical guideline.**

- Developed for pre-medical educational purposes and medical school application portfolio
- NOT approved for clinical use without institutional review and attending physician oversight
- All clinical decisions require attending anesthesiologist judgment and patient-specific assessment
- Does not replace formal anesthesia training, credentialing, or institutional policies
- Author is pre-medical student; content reflects literature synthesis, not clinical expertise

**For clinical implementation:** This framework requires validation by board-certified anesthesiologists, institutional governance review, pharmacy approval, and integration with local policies. No protocol substitutes for individualized patient assessment and attending-level clinical judgment.

---

## Why This Is the First-Line Preferred Pathway

**Optimal Outcomes Profile:**
- Highest-quality analgesia (regional blocks + multimodal systemic agents)
- Lowest PONV risk (typically 3-8% vs 25-40% with opioid-based techniques)
- Zero intraoperative opioids
- Smooth, calm emergence with minimal sedation
- Excellent patient satisfaction

**Best For:**
- High PONV risk patients (Apfel ≥3)
- Baker Grade III-IV capsular contracture requiring extensive dissection
- Suspected or confirmed implant infection with washout
- Anxious patients or those with history of difficult emergence
- Patient request for opioid-free care
- Extensive pocket work or revision complexity anticipated

**Evidence Base:**
- ASRA Practice Advisory on regional anesthesia for breast surgery (2023)
- ERAS Society guidelines for breast reconstruction (2023-2024)
- Multiple RCTs demonstrating PECS block efficacy for breast procedures
- Multimodal opioid-free anesthesia reduces PONV, improves recovery metrics

---

## Indications

**Surgical:**
- Post-mastectomy implant revision (any etiology)
- Capsular contracture (Baker Grade I-IV)
- Implant malposition or rotation
- Size exchange or implant removal
- Suspected/confirmed infection requiring washout
- Acellular dermal matrix (ADM) revision

**Patient Factors:**
- ASA I-III
- Apfel PONV score ≥2 (strong preference for score ≥3)
- Patient consent for regional anesthesia
- Able to tolerate supine positioning for block placement

---

## Contraindications

### Absolute Contraindications

| Contraindication | Rationale |
|------------------|-----------|
| **Local infection at block site** | Risk of seeding deep tissue infection |
| **True local anesthetic allergy** | No safe alternative for regional block |
| **Patient refusal after informed discussion** | Autonomy; proceed to Protocol 2 or 3 |
| **Coagulopathy with active bleeding** | Unacceptable bleeding risk |

### Relative Contraindications (Assess Risk-Benefit)

| Consideration | Management Strategy |
|---------------|---------------------|
| **Therapeutic anticoagulation** | Hold per ASRA guidelines; assess urgency vs bleeding risk |
| **Severe COPD / CO₂ retention** | May tolerate poorly; monitor closely; consider avoiding dexmedetomidine bolus |
| **Baseline bradycardia (HR <50)** | Avoid or minimize dexmedetomidine; monitor HR continuously |
| **Significant hepatic dysfunction** | Reduce lidocaine infusion dose or avoid; monitor for toxicity |
| **Renal impairment (severe)** | Caution with NSAIDs; adjust multimodal regimen |
| **Prior chest wall radiation** | May have tissue fibrosis; ultrasound may be more challenging |
| **Morbid obesity** | May require longer needle; increased technical difficulty |

---

## Required Equipment and Preparation

### Regional Anesthesia Equipment

**Ultrasound:**
- High-frequency linear probe (10-15 MHz)
- Sterile ultrasound sleeve and gel

**Block Needles:**
- 22G, 80-100 mm echogenic block needle (preferred)
- Extension tubing for injection

**Local Anesthetic (Choose ONE):**

**Preferred: Ropivacaine 0.2%**
- Lower cardiotoxicity than bupivacaine
- Adequate sensory block with reduced motor block
- Total volume: 30-40 mL for bilateral PECS I + II

**Alternative: Bupivacaine 0.25%**
- Slightly longer duration
- Higher cardiotoxicity risk; requires strict aspiration technique
- Total volume: 25-35 mL for bilateral PECS I + II

**Additives (Optional):**
- Dexamethasone 2-4 mg (may prolong block duration 2-4 hours)
- Epinephrine 1:200,000-1:400,000 (increases safe dose ceiling, may prolong duration)

**Safety Equipment:**
- 20% lipid emulsion immediately available (LAST treatment)
- Resuscitation cart with airway equipment
- ACLS medications

### Monitoring Equipment

**Standard ASA Monitors:**
- Continuous ECG
- Pulse oximetry
- Non-invasive blood pressure (cycle q3-5 min)
- Capnography (continuous during intubation)
- Temperature monitoring
- Inspired/expired gas analysis

**Consider Adding:**
- Processed EEG (BIS, Entropy) if age >70, frailty, or desire for tight depth control
- Arterial line only if severe cardiac disease (rarely needed)

---

## Preoperative Preparation

### Multimodal Oral Premedication (Given 1-2 Hours Preoperatively)

| Medication | Dose | Indications | Contraindications |
|------------|------|-------------|-------------------|
| **Acetaminophen** | 1000 mg PO | **All patients** (unless hepatic dysfunction) | Severe hepatic impairment |
| **Celecoxib** | 200-400 mg PO | If no renal/GI contraindications | CKD stage 4-5, active PUD, ASA allergy |
| **Gabapentin** | **NOT routinely recommended** | Consider ONLY if neuropathic pain or severe anxiety AND age <65 | Age >75, cognitive impairment, OSA |

**Gabapentin Note:**
- Modern ERAS guidelines do NOT routinely recommend gabapentin due to sedation/delirium risk
- If used: 300 mg maximum (lower end of range)
- Avoid in elderly, cognitively impaired, or OSA patients

### Anxiolysis (In Block Room, If Needed)

| Medication | Dose | Notes |
|------------|------|-------|
| **Midazolam** | 1-2 mg IV | Only if very anxious; titrate slowly |
| | | Avoid if elderly or significant OSA |

### Antibiotic Prophylaxis

| Weight | Medication | Timing |
|--------|------------|--------|
| **<120 kg** | Cefazolin 2 g IV | 30-60 min before incision |
| **≥120 kg** | Cefazolin 3 g IV | 30-60 min before incision |
| **β-lactam allergy** | Vancomycin 15 mg/kg IV (max 2 g) | 60-120 min before incision (slower infusion) |

**Re-dosing:**
- Cefazolin: q4h if case duration >4 hours
- Vancomycin: q12h (rarely needed for breast surgery duration)

### Antiemetic Prophylaxis (If Apfel ≥2)

**Preoperative (Choose 1-2 Based on Risk):**

| Apfel Score | Medications |
|-------------|-------------|
| **2** | Dexamethasone 4-8 mg IV |
| **3** | Dexamethasone 4-8 mg IV + Ondansetron 4 mg IV (before emergence) |
| **4** | Dexamethasone 8 mg IV + Scopolamine patch + Ondansetron 4 mg IV (before emergence) |

---

## Regional Block Technique

### Patient Positioning and Preparation

**Positioning:**
- Supine with arm abducted 90° on armboard
- OR: Arm across chest if performing blocks after induction (less ideal)

**Sterile Technique:**
- Chlorhexidine or povidone-iodine skin prep
- Sterile gloves, mask
- Sterile ultrasound sleeve and gel

**Time-Out:**
- Verify correct surgical side
- Confirm local anesthetic type, concentration, and total dose
- Review patient allergies
- Ensure lipid emulsion available

### PECS I Block (Interfascial Plane Block)

**Target Plane:**
- Between **pectoralis major** and **pectoralis minor** muscles
- Blocks lateral and medial pectoral nerves

**Ultrasound Technique:**
- High-frequency linear probe in parasagittal plane
- Identify pec major (superficial) and pec minor (deep)
- Advance needle in-plane from lateral to medial
- Deposit local anesthetic between muscles

**Volume:**
- **10-15 mL per side** (ropivacaine 0.2% or bupivacaine 0.25%)

**Endpoint:**
- Separation of pec major and pec minor with local anesthetic spread

### PECS II Block (Extends Coverage to Lateral Chest Wall)

**Target Plane:**
- Between **pectoralis minor** and **serratus anterior** muscles
- Blocks intercostal nerves T2-T6, long thoracic nerve

**Ultrasound Technique:**
- Same probe position, advance deeper
- Identify pec minor (superficial), serratus anterior (deep), and ribs
- Needle passes through pec minor to reach serratus plane
- Deposit local anesthetic between pec minor and serratus

**Volume:**
- **20-25 mL per side** (ropivacaine 0.2% or bupivacaine 0.25%)

**Endpoint:**
- Spread along chest wall between pec minor and serratus anterior

### Alternative: Serratus Anterior Plane (SAP) Block

**If PECS II technically difficult:**
- Target plane: Between serratus anterior and intercostal muscles
- More superficial, may be easier in obese patients
- Similar volume (20-25 mL per side)

### Local Anesthetic Dosing and Safety

**Total Bilateral PECS I + II Dosing:**

| Local Anesthetic | PECS I (each side) | PECS II (each side) | Total Volume | Total Dose | Max Safe Dose |
|------------------|-------------------|---------------------|--------------|------------|---------------|
| **Ropivacaine 0.2%** | 10-15 mL | 20-25 mL | 60-80 mL | 120-160 mg | 3 mg/kg (~200 mg for 70 kg with epi) |
| **Bupivacaine 0.25%** | 10 mL | 15-20 mL | 50-60 mL | 125-150 mg | 2.5 mg/kg (~175 mg for 70 kg with epi) |

**Safety Notes:**
- **Always aspirate before injection** (every 3-5 mL)
- Inject incrementally with frequent aspiration
- Monitor for signs of local anesthetic systemic toxicity (LAST):
  - Early: Perioral numbness, metallic taste, tinnitus, dizziness
  - Severe: Seizures, cardiovascular collapse
- **20% lipid emulsion at bedside** (1.5 mL/kg bolus, then 0.25 mL/kg/min infusion if LAST)

**Lower Concentrations Preferred:**
- Ropivacaine 0.2% provides excellent sensory block with lower total milligram dose
- Reduces toxicity risk while maximizing volume/spread

### Block Assessment

**Sensory Testing (5-10 Minutes Post-Block):**
- Test T2-T6 dermatomes with cold or pinprick
- Expect diminished sensation over anterior/lateral chest wall
- Document dermatomal coverage

**If Block Inadequate:**
- Consider supplemental infiltration by surgeon
- Increase systemic multimodal agents
- Have low threshold for opioid rescue if needed

---

## Induction of General Anesthesia

### Pre-Induction Setup

**Patient Positioning:**
- Supine, arms tucked or on armboards
- Pressure point padding

**Monitoring:**
- Standard ASA monitors connected and functioning
- Baseline vital signs documented

**Pre-Oxygenation:**
- 100% O₂ for 3-5 minutes
- Target end-tidal O₂ >90%

### Induction Sequence (Opioid-Free)

| Step | Agent | Dose | Purpose | Notes |
|------|-------|------|---------|-------|
| **1** | **Lidocaine** | 1.5 mg/kg IV (max 100 mg) | Blunt sympathetic response to laryngoscopy | Give 90 seconds before laryngoscopy if possible |
| **2** | **Ketamine** (optional) | 0.2-0.3 mg/kg IV | Analgesia, NMDA antagonism | Consider if anticipated pain; omit if hypertension concern |
| **3** | **Propofol** | 1.5-2 mg/kg IV | Induction of unconsciousness | **Reduce to 1-1.5 mg/kg if:** Age >70, frail, ASA III-IV |
| **4** | **Rocuronium** | 0.6-1 mg/kg IV | Neuromuscular blockade | Or succinylcholine 1-1.5 mg/kg if RSI indicated |

**Elderly/Frail Dosing Adjustments:**
- Propofol: 1-1.5 mg/kg (reduce 25-33%)
- Ketamine: 0.1-0.2 mg/kg (reduce 33-50%)
- Titrate slowly; allow time for circulation

**Contraindications to Ketamine:**
- Uncontrolled hypertension (SBP >180)
- Recent MI or unstable angina
- Active psychosis
- Severe coronary artery disease (relative)

### Airway Management

**Endotracheal Intubation (Preferred):**
- Video laryngoscopy preferred for optimal view
- ETT size: 7.0-7.5 mm (women), 7.5-8.0 mm (men)
- Cuff pressure 20-30 cm H₂O

**Supraglottic Airway (LMA):**
- Acceptable alternative if short case and low aspiration risk
- Size 3-4 (women), 4-5 (men)

**Confirm Placement:**
- End-tidal CO₂ waveform
- Bilateral breath sounds
- Chest rise

---

## Maintenance of Anesthesia

### Hypnotic Agent (Choose ONE)

**Option A: Propofol TIVA (Preferred for PONV Prophylaxis)**

| Parameter | Dosing |
|-----------|--------|
| **Infusion Rate** | 75-150 mcg/kg/min (4.5-9 mg/kg/hr) |
| **Elderly/Frail** | 50-100 mcg/kg/min (3-6 mg/kg/hr) |
| **Target** | BIS 40-60 or clinical signs of adequate depth |

**Option B: Volatile Anesthetic (Sevoflurane/Desflurane)**

| Parameter | Dosing |
|-----------|--------|
| **MAC** | 0.7-1.0 MAC (age-adjusted) |
| **Sevoflurane** | 1.5-2.5% end-tidal |
| **Desflurane** | 4-6% end-tidal |

**Note:** Propofol TIVA preferred for PONV reduction in high-risk patients

### Multimodal Adjuncts (All Given - Core of OFIA)

#### Dexmedetomidine Infusion

| Parameter | Dosing | Notes |
|-----------|--------|-------|
| **Loading Dose** | **AVOID** or 0.2-0.3 mcg/kg over 10 min | High risk of bradycardia/hypotension with bolus |
| **Maintenance** | 0.2-0.5 mcg/kg/hr | Start low, titrate to effect |
| **Elderly/Frail** | 0.2-0.4 mcg/kg/hr | Use lower end of range |
| **Taper** | Stop or reduce 10-15 min before end | Prevent prolonged sedation |

**Monitoring:**
- Continuous HR and BP
- If HR <50 or symptomatic bradycardia → reduce or stop infusion
- If MAP <65 persistently → reduce dose, consider phenylephrine

**Contraindications:**
- High-grade AV block without pacemaker
- Severe bradycardia (HR <45)
- Decompensated heart failure

#### Lidocaine Infusion

| Parameter | Dosing | Notes |
|-----------|--------|-------|
| **Bolus** | 1.5 mg/kg IV at induction | Already given |
| **Maintenance** | 1-2 mg/kg/hr (typical: 1.5 mg/kg/hr) | Anti-inflammatory, analgesic |
| **Hepatic Dysfunction** | 0.5-1 mg/kg/hr or avoid | Reduced clearance |
| **Duration** | Continue through case, stop at closure | Or continue 1-2 hr postop per institutional protocol |

**Contraindications:**
- Severe heart block without pacemaker
- Severe hepatic dysfunction
- Allergy to amide local anesthetics

#### Ketamine (Optional - Consider for Enhanced Analgesia)

**Option A: Induction Bolus Only**
- 0.2-0.3 mg/kg at induction (already given if used)
- No additional intraoperative dosing

**Option B: Intermittent Microboluses**
- 10-20 mg IV boluses for surgical stimulus
- Total cumulative dose typically 0.3-0.5 mg/kg

**Option C: Continuous Infusion (Uncommon)**
- 0.1-0.2 mg/kg/hr
- Adds cost; intermittent dosing usually sufficient

**Not a Substitute for Adequate Depth:**
- Ensure propofol/volatile agent adequate first
- Ketamine is analgesic adjunct, not primary hypnotic

### Ventilation Strategy

**Lung-Protective Ventilation:**

| Parameter | Target |
|-----------|--------|
| **Tidal Volume** | 6-8 mL/kg ideal body weight |
| **Respiratory Rate** | 10-14 breaths/min (adjust for EtCO₂) |
| **PEEP** | 5-8 cm H₂O |
| **FiO₂** | 0.4-0.5 (target SpO₂ >94%) |
| **EtCO₂** | 35-40 mmHg |

**Avoid:**
- Excessive tidal volumes (>10 mL/kg)
- Hyperventilation (EtCO₂ <30)
- FiO₂ >0.8 unless hypoxemic (ERAS guideline)

---

## Intraoperative Management

### Hemodynamic Goals

| Parameter | Target Range | Management |
|-----------|--------------|------------|
| **MAP** | 65-90 mmHg (or ±20% of baseline) | Phenylephrine 50-100 mcg IV for hypotension |
| **Heart Rate** | 50-90 bpm | Reduce dex if <50; glycopyrrolate 0.2 mg if symptomatic |
| **SpO₂** | ≥94% | Increase FiO₂, check ventilator settings |

**Hypotension Management:**
- **First-line:** Phenylephrine 50-100 mcg IV bolus (pure alpha agonist, minimal HR effect)
- **If bradycardic:** Ephedrine 5-10 mg IV (mixed alpha/beta)
- **Persistent:** Reduce dexmedetomidine, ensure adequate fluid status

**Bradycardia Management:**
- **Asymptomatic, HR >45:** Observe, reduce dexmedetomidine
- **Symptomatic or HR <45:** Glycopyrrolate 0.2-0.4 mg IV
- **Severe (<40):** Stop dexmedetomidine, atropine 0.5-1 mg IV

### Fluid Management

**Goal-Directed, Restrictive Strategy (ERAS Principles):**

| Fluid Type | Rate | Total |
|------------|------|-------|
| **Crystalloid** | 2-4 mL/kg/hr maintenance | Goal: <1500 mL total for 1-2 hr case |
| **Replacement** | 1:1 for estimated blood loss | Typically minimal in breast revision |

**Avoid Excessive Fluids:**
- Associated with edema, delayed recovery, increased PONV
- Use vasopressors to maintain MAP rather than fluid boluses

### Temperature Management

**Maintain Normothermia:**
- Forced air warming blanket
- Warmed IV fluids if large volume
- Target core temperature >36°C

**Avoid Hypothermia:**
- Increases infection risk, coagulopathy, shivering, discomfort

### Antiemetic Administration

**If Not Given Preoperatively:**

| Apfel Score | Intraoperative Strategy |
|-------------|------------------------|
| **2-3** | Dexamethasone 4 mg IV (if not already given) |
| **4** | Dexamethasone 8 mg IV + Ondansetron 4 mg IV before emergence |

---

## Emergence and Extubation

### Emergence Protocol (~10-15 Minutes Before Anticipated End)

**Taper Infusions:**

| Agent | Taper Strategy |
|-------|----------------|
| **Dexmedetomidine** | Stop or reduce to 0.1-0.2 mcg/kg/hr 10-15 min before end |
| **Lidocaine** | Stop at skin closure or continue 1-2 hr postop per protocol |
| **Ketamine** | Stop 5-10 min before end if infusion used |
| **Propofol** | Taper for awakening at skin closure; target BIS 70-80 for emergence |

**Antiemetic Prophylaxis:**
- **Ondansetron 4 mg IV** before emergence (if not already given and Apfel ≥2)
- Consider **additional agent** if Apfel 4 and high-risk patient

**Neuromuscular Blockade Reversal:**
- **Sugammadex 2-4 mg/kg IV** (preferred for reliable reversal)
  - 2 mg/kg if TOF 2-4 twitches
  - 4 mg/kg if TOF 0-1 twitch or deep block
- **OR Neostigmine 0.04-0.07 mg/kg + Glycopyrrolate 0.01 mg/kg**
  - Only if TOF ≥2 twitches
  - Max neostigmine 5 mg

### Extubation Criteria

**Standard Extubation (For Protocols 1-2 - OFIA):**

| Criterion | Assessment |
|-----------|------------|
| **Awake** | Following commands, eyes open |
| **Adequate Ventilation** | RR 10-20, strong respiratory effort, VT >5 mL/kg |
| **Oxygenation** | SpO₂ >92% on minimal supplemental O₂ |
| **Hemodynamics** | Stable HR and BP |
| **Neuromuscular Function** | TOF ratio >0.9, sustained head lift >5 sec, strong hand grip |

**Do NOT Extubate If:**
- Somnolent (RASS ≤-2)
- Inadequate ventilation or oxygenation
- Hemodynamically unstable
- Residual neuromuscular blockade (TOF <0.9)

**Post-Extubation:**
- 100% O₂ by face mask initially
- Encourage deep breathing
- Position head-up 30-45°

---

## PACU Management

### Expected Clinical Course

**Typical Protocol 1 PACU Course:**
- **Pain:** NRS 1-3/10 (excellent analgesia from blocks)
- **Sedation:** Awake, calm (RASS 0)
- **PONV:** Low risk (3-8%)
- **Hemodynamics:** Stable
- **Duration:** 60-90 minutes to discharge readiness

### Monitoring Requirements

| Parameter | Frequency | Duration |
|-----------|-----------|----------|
| **Vital Signs** | Q15 min initially → Q30 min when stable | Until discharge |
| **Pulse Oximetry** | Continuous until stable and awake | ~60 min |
| **RASS Score** | Q30 min | Until discharge |
| **Pain Score (NRS)** | Q30 min | Until discharge |

### Pain Management (Multimodal Foundation)

**Scheduled Non-Opioid Analgesics:**

| Medication | Dose | Frequency | Notes |
|------------|------|-----------|-------|
| **Acetaminophen** | 1000 mg PO | Q6h scheduled | If not already given preop |
| **Ketorolac** | 15 mg IV | Q6h × 48 hours | **Preferred NSAID** for first-line |
| **OR Celecoxib** | 200 mg PO | Q12h | Alternative if ketorolac contraindicated |

**Contraindications to NSAIDs:**
- CKD stage 4-5 (eGFR <30)
- Active peptic ulcer disease
- ASA/NSAID allergy
- Severe hepatic dysfunction

### Rescue Analgesia Protocol

**If Pain NRS ≥4 Despite Scheduled Multimodal:**

**Step 1: Verify Block Function**
- Assess sensory distribution (T2-T6 dermatomes)
- If block working but pain persistent → likely visceral or inadequate coverage
- If block clearly failed → escalate to attending, consider rescue interventions

**Step 2: Rescue Options (If Block Adequate)**

| Pain Level | First-Line Rescue | Second-Line |
|------------|-------------------|-------------|
| **NRS 4-6** | Ketamine 10-20 mg IV (if institutional protocol permits) | Hydromorphone 0.2-0.4 mg IV q15-20 min |
| **NRS ≥7** | Hydromorphone 0.2-0.4 mg IV q15-20 min | Consider attending evaluation for rescue block |

**Opioid Rescue Phenotype Adjustments:**

| Patient Phenotype | Hydromorphone Dose | Interval | Monitoring |
|-------------------|-------------------|----------|------------|
| **Opioid-naïve, elderly, frail** | 0.2 mg IV | Q20-30 min | Continuous SpO₂ |
| **Standard adult** | 0.2-0.4 mg IV | Q15-20 min | Continuous SpO₂ until stable |
| **Chronic opioid use** | 0.4-0.8 mg IV | Q15-20 min | Higher tolerance expected |
| **OSA** | 0.2 mg IV | Q30 min | Enhanced monitoring, lower threshold for capnography |

**If High Rescue Needs:**
- Reassess multimodal regimen adequacy
- Consider ketamine infusion (0.1-0.2 mg/kg/hr) if institutional protocol allows
- Attending anesthesiologist evaluation
- Possible rescue regional anesthesia or surgeon infiltration

### PONV Management

**Prevention (Already Done):**
- TIVA with propofol (if used)
- Dexamethasone preoperatively
- Ondansetron before emergence

**Treatment If PONV Occurs (Despite Prophylaxis):**

| Episode | Treatment | Dose |
|---------|-----------|------|
| **First** | Ondansetron | 4 mg IV (if not already given) |
| **Second** | Metoclopramide | 10 mg IV |
| **Third** | Promethazine | 6.25-12.5 mg IV (sedating) |
| **Refractory** | Haloperidol | 0.5-1 mg IV (off-label, effective) |

### Discharge Readiness Criteria

**Modified Aldrete Score ≥9 (PACU Discharge):**

| Criterion | Score |
|-----------|-------|
| **Activity** | Moves 4 extremities = 2; Moves 2 extremities = 1; No movement = 0 |
| **Respiration** | Deep breathing, coughing = 2; Dyspnea, shallow = 1; Apnea = 0 |
| **Circulation** | BP ±20 mmHg baseline = 2; BP ±20-50 mmHg = 1; BP ±>50 mmHg = 0 |
| **Consciousness** | Fully awake = 2; Arousable = 1; Not responding = 0 |
| **O₂ Saturation** | SpO₂ >92% room air = 2; SpO₂ >90% with O₂ = 1; SpO₂ <90% with O₂ = 0 |

**Additional Criteria:**
- Pain controlled (NRS ≤4 with plan)
- No active PONV or controlled with medications
- Surgical site stable (no excessive bleeding/hematoma)
- Patient meets institutional discharge criteria

---

## Postoperative Analgesia Plan (Home)

### Scheduled Medications (48-72 Hours)

| Medication | Dose | Frequency | Duration |
|------------|------|-----------|----------|
| **Acetaminophen** | 1000 mg PO | Q6h scheduled | 48-72 hours |
| **Ibuprofen** | 400-600 mg PO | Q6h scheduled | 48-72 hours |
| **OR Celecoxib** | 200 mg PO | Q12h scheduled | 48-72 hours (if ibuprofen not tolerated) |

### Rescue Opioid (Rarely Needed with Protocol 1)

**If Prescribed (Should Be Minimal Need):**
- Oxycodone 5 mg PO Q4-6h PRN severe pain
- Typically ≤10 tablets dispensed
- Counsel on storage, disposal, risks

**Many Protocol 1 Patients Require NO Opioid Prescription:**
- Excellent block + multimodal often sufficient
- Consider opioid-free discharge if pain NRS ≤3 and patient confident

---

## Key Safety Considerations

### Local Anesthetic Systemic Toxicity (LAST)

**Prevention:**
- Use lowest effective concentration and volume
- Aspirate frequently during injection
- Inject incrementally (3-5 mL aliquots)
- Monitor patient during and after block

**Early Recognition:**

| Phase | Signs/Symptoms |
|-------|----------------|
| **CNS Excitation** | Perioral numbness, metallic taste, tinnitus, dizziness, agitation, slurred speech |
| **CNS Depression** | Drowsiness, loss of consciousness, **seizures** |
| **Cardiovascular** | Hypertension, tachycardia → hypotension, bradycardia, **arrhythmias, cardiac arrest** |

**Treatment (LAST Protocol):**

**1. Stop Injection + Call for Help**

**2. Airway Management:**
- 100% O₂
- Avoid hyperventilation (worsens acidosis)
- Consider intubation if seizing or unconscious

**3. Seizure Management:**
- Benzodiazepines (midazolam 2-5 mg IV) or propofol (small doses)
- Avoid large propofol doses (can worsen cardiovascular collapse)

**4. 20% Lipid Emulsion (IMMEDIATE):**
- **Bolus:** 1.5 mL/kg IV over 1 minute (~100 mL for 70 kg)
- **Infusion:** 0.25 mL/kg/min (~18 mL/min for 70 kg)
- Repeat bolus q3-5 min if persistent cardiovascular collapse
- **Maximum:** ~10 mL/kg over 30 minutes

**5. ACLS with Modifications:**
- Reduce epinephrine doses (<1 mcg/kg)
- Avoid vasopressin, calcium channel blockers, beta-blockers, propofol
- Prolonged resuscitation may be needed (lipid takes time)

**6. Post-Resuscitation:**
- Monitor ≥4-6 hours (lipid complications: pancreatitis, ARDS)
- Cardiology consultation if cardiac arrest occurred

### Dexmedetomidine Adverse Effects

**Bradycardia:**
- Most common side effect (5-15% incidence)
- Monitor HR continuously
- **If HR <50:** Reduce or stop infusion
- **If symptomatic or HR <45:** Glycopyrrolate 0.2-0.4 mg IV

**Hypotension:**
- Dose-dependent (10-20% incidence)
- **If MAP <65:** Reduce infusion, phenylephrine 50-100 mcg IV
- **If persistent:** Stop infusion, ensure adequate fluid status

**Biphasic Response:**
- Initial hypertension possible with rapid bolus (peripheral alpha-2 vasoconstriction)
- Avoid loading dose or give slowly over 10 minutes

### Ketamine Adverse Effects

**Emergence Reactions:**
- Rare at analgesic doses (0.2-0.5 mg/kg total)
- Prophylaxis: Benzodiazepine if high-risk (history of psychiatric disorder)
- Treatment: Reassurance, low-dose midazolam 1-2 mg IV

**Hypertension/Tachycardia:**
- Sympathomimetic effect
- Usually mild and transient
- **If severe:** Reduce dose, ensure adequate depth of anesthesia

**Contraindications:**
- Active psychosis, schizophrenia
- Uncontrolled hypertension (SBP >180)
- Recent MI or unstable angina (relative)

### Airway Complications

**Bronchospasm:**
- Rare with modern anesthetics
- Treatment: Deepen anesthesia, 100% O₂, albuterol, consider IV lidocaine 1 mg/kg

**Laryngospasm:**
- Risk higher with light anesthesia or airway irritation
- Treatment: 100% O₂, jaw thrust, CPAP, deepen anesthesia, succinylcholine 0.1-0.5 mg/kg if severe

**Aspiration:**
- Low risk in fasted, elective patients
- Higher risk if inadequate NPO, GERD, obesity
- Prevention: Pre-oxygenation, cricoid pressure if RSI indicated, appropriate fasting

---

## Troubleshooting Common Scenarios

### Scenario 1: Inadequate Block Coverage

**Recognition:**
- Patient reports pain despite documented block placement
- Sensory testing shows patchy or absent coverage

**Management:**
1. **Intraoperative:** Increase systemic multimodal agents (ketamine boluses, increase dex/lidocaine)
2. **Consider supplemental surgeon infiltration**
3. **PACU:** Liberal rescue analgesia as per protocol
4. **If severe:** Attending evaluation, consider rescue block or conversion to Protocol 2/3 strategy

**Prevention:**
- Meticulous ultrasound-guided technique
- Adequate volume (30-40 mL total bilateral)
- Proper plane identification
- Consider adding dexamethasone to prolong block

### Scenario 2: Excessive Sedation in PACU

**Recognition:**
- RASS score ≤-2 (moderate to deep sedation)
- Difficult to arouse, not following commands
- Adequate oxygenation and ventilation maintained

**Likely Causes:**
- Dexmedetomidine effect (long context-sensitive half-time)
- Residual propofol
- Gabapentin if given preoperatively

**Management:**
1. **Ensure adequate ventilation and oxygenation**
   - Continuous SpO₂ monitoring
   - Supplemental O₂ if needed
   - Consider capnography if concerns about ventilation

2. **Supportive care:**
   - Allow time for drug elimination
   - Verbal and tactile stimulation
   - Do NOT give reversal agents (dexmedetomidine has none)

3. **Extended monitoring:**
   - Keep in PACU until RASS ≥-1
   - Lower threshold for monitored bed if prolonged

4. **Future cases:**
   - Reduce dexmedetomidine dose (use 0.2-0.3 mcg/kg/hr)
   - Ensure proper taper before emergence
   - Avoid gabapentin preoperatively

**Do NOT Discharge Until:**
- RASS ≥0 (alert and calm)
- Following commands consistently
- Adequate ventilation without intervention

### Scenario 3: Intraoperative Hypertension

**Recognition:**
- SBP >20% above baseline or MAP >100 mmHg
- Sustained elevation (not just brief spike)

**Differential Diagnosis:**
- Light anesthesia (inadequate depth)
- Surgical stimulation
- Ketamine effect
- Full bladder
- Hypercarbia

**Management:**
1. **Assess depth:** Check BIS/Entropy if available, clinical signs (movement, tearing, sweating)
2. **Increase hypnotic:** Increase propofol infusion or volatile concentration
3. **Verify ventilation:** Check EtCO₂, ensure adequate minute ventilation
4. **Consider additional ketamine:** 10-20 mg bolus for surgical stimulus
5. **Pharmacologic treatment if persistent:**
   - Labetalol 5-10 mg IV (alpha + beta blockade)
   - Hydralazine 5-10 mg IV (direct vasodilator)
   - Avoid in ketamine-related hypertension (usually transient)

**Prevention:**
- Adequate depth before surgical incision
- Liberal use of lidocaine bolus before stimulation
- Anticipate painful moments (dissection, capsulectomy)

### Scenario 4: Bradycardia During Maintenance

**Recognition:**
- HR <50 bpm
- May or may not be symptomatic (hypotension, dizziness)

**Likely Cause:**
- Dexmedetomidine (most common with this protocol)

**Management:**

**If HR 45-50 and asymptomatic:**
1. Reduce dexmedetomidine to 0.1-0.2 mcg/kg/hr
2. Monitor closely
3. No immediate treatment needed

**If HR <45 or symptomatic:**
1. **Stop dexmedetomidine immediately**
2. Glycopyrrolate 0.2-0.4 mg IV (preferred over atropine - less tachycardia, no CNS effects)
3. Monitor for response over 3-5 minutes
4. **If severe (HR <40):** Atropine 0.5-1 mg IV

**If associated hypotension:**
- Ephedrine 5-10 mg IV (mixed alpha/beta agonist)
- Increases both HR and BP

**Prevention:**
- Avoid dexmedetomidine loading bolus
- Use lower infusion rates (0.2-0.3 mcg/kg/hr) in elderly or baseline bradycardia
- Monitor HR continuously

### Scenario 5: Difficult Block Placement (Obese Patient)

**Recognition:**
- Poor ultrasound visualization
- Difficulty identifying fascial planes
- Uncertain needle tip location

**Management:**

**Ultrasound Optimization:**
1. Increase depth setting to visualize deeper structures
2. Adjust gain to optimize tissue differentiation
3. Use color Doppler to identify vessels
4. Try different probe positions/angles

**Technical Adjustments:**
1. Use longer needle (100 mm vs 80 mm)
2. Consider more lateral approach for better angle
3. Liberal use of hydrodissection (inject small volume to confirm plane before full dose)
4. Consider performing blocks after induction (patient supine, arm positioned, deeper anesthesia)

**Alternative Approaches:**
1. **Serratus Anterior Plane (SAP) block:** More superficial, may be easier to visualize
2. **Paravertebral block:** Alternative if PECS technically impossible (requires advanced skill)
3. **Surgeon infiltration:** If blocks not feasible, ensure robust surgeon field block
4. **Convert to Protocol 2:** Enhanced systemic multimodal without blocks

**When to Abandon Block Attempt:**
- Multiple unsuccessful attempts (>3 passes per side)
- Unable to confidently identify anatomy
- Patient discomfort despite adequate sedation
- Time constraints
- **Safety first:** Better to have no block than unsafe block

---

## Protocol Modifications for Special Populations

### Elderly Patients (Age >70)

**Pharmacologic Adjustments:**

| Agent | Standard Dose | Elderly Dose | Rationale |
|-------|---------------|--------------|-----------|
| **Propofol induction** | 1.5-2 mg/kg | **1-1.5 mg/kg** | Reduced cardiac output, increased brain sensitivity |
| **Propofol maintenance** | 75-150 mcg/kg/min | **50-100 mcg/kg/min** | Reduced clearance |
| **Dexmedetomidine** | 0.2-0.5 mcg/kg/hr | **0.2-0.4 mcg/kg/hr** | Increased sensitivity, bradycardia risk |
| **Ketamine** | 0.2-0.3 mg/kg | **0.1-0.2 mg/kg** | Reduced volume of distribution |
| **Rocuronium** | 0.6-1 mg/kg | **0.6 mg/kg** | Use lower end; prolonged effect possible |

**Additional Considerations:**
- **Avoid or minimize gabapentin** (delirium risk)
- **Processed EEG monitoring recommended** (BIS/Entropy)
- **Gentle fluid management** (cardiac reserve may be limited)
- **Slower medication titration** (allow time for circulation)
- **Enhanced PACU monitoring** (delayed emergence possible)

### Obese Patients (BMI >35)

**Dosing Considerations:**

| Agent | Dosing Weight |
|-------|---------------|
| **Propofol** | Total body weight (TBW) |
| **Rocuronium** | Ideal body weight (IBW) |
| **Local anesthetics** | IBW (mg/kg limits still apply) |
| **Dexmedetomidine** | IBW or adjusted body weight |
| **Antibiotics** | Weight-based per protocol (cefazolin 3g if >120 kg) |

**Technical Considerations:**
- Longer block needles may be needed (100 mm)
- Ultrasound penetration may be limited (increase depth, adjust gain)
- Consider blocks after induction for positioning comfort
- Ensure adequate armboard/table weight capacity

**Airway Management:**
- Lower threshold for video laryngoscopy
- Have difficult airway equipment available
- Consider ramped positioning for intubation

**Enhanced Monitoring:**
- OSA screening (STOP-BANG)
- If OSA present: Enhanced PACU monitoring, continuous SpO₂, lower opioid threshold

### Patients with Chronic Opioid Use

**Special Considerations:**
- **Protocol 1 still appropriate** (blocks + multimodal may reduce opioid needs)
- **Higher breakthrough pain expected** (tolerance)
- **Anticipate higher rescue analgesic requirements**

**Modifications:**
- **Consider higher-end multimodal dosing:**
  - Ketamine 0.3-0.5 mg/kg induction bolus
  - Ketamine infusion 0.1-0.2 mg/kg/hr or microboluses 20 mg q30-60min
  - Dexmedetomidine upper end of range (0.4-0.5 mcg/kg/hr)

- **PACU rescue analgesia:**
  - Hydromorphone 0.4-0.8 mg IV q15-20 min (anticipate tolerance)
  - Lower threshold for ketamine 20-30 mg IV boluses
  - May require higher total opioid doses than opioid-naïve patients

- **Postoperative plan:**
  - Continue home opioid regimen (do NOT discontinue chronic therapy)
  - Prescribe additional short-acting opioid for breakthrough pain
  - Coordinate with pain management/primary care
  - Emphasize multimodal non-opioid strategies

**Alternative:** If very high opioid tolerance or patient preference, consider **Protocol 3** with enhanced opioid dosing adjusted for tolerance.

### Patients with Significant Cardiac Disease

**Risk Assessment:**
- Recent MI (<6 months): High risk, consider postponing if elective
- Heart failure: Assess functional status, volume status
- Valvular disease: Know severity, obtain cardiology clearance if severe
- Arrhythmias: Ensure rate/rhythm controlled

**Anesthetic Modifications:**

**Avoid or Use Cautiously:**
- Large propofol boluses (myocardial depression)
- Dexmedetomidine loading dose (hypertension then hypotension)
- Ketamine if recent MI/unstable angina (sympathomimetic)

**Hemodynamic Goals:**
- Tighter MAP control (avoid swings)
- Maintain sinus rhythm if possible
- Avoid tachycardia (increases myocardial O₂ demand)

**Monitoring:**
- Consider arterial line if severe disease
- Continuous ST-segment monitoring (if CAD)
- Have cardiac medications available (beta-blockers, nitroglycerin, amiodarone)

**Fluid Management:**
- Conservative crystalloid (risk of volume overload)
- Vasopressors preferred over fluid boluses for hypotension

---

## Documentation Requirements

### Preoperative Note

**Required Elements:**
- Informed consent documented (general anesthesia, regional block, risks/benefits/alternatives)
- NPO status verified
- Allergies confirmed
- ASA classification assigned
- Apfel PONV score calculated
- Anesthesia plan documented (Protocol 1 selected, rationale)
- Block planned (PECS I + II bilateral) with patient consent
- Multimodal medications administered preoperatively

### Intraoperative Record

**Regional Block Documentation:**
- Time-out performed (correct side, patient, procedure)
- Ultrasound-guided technique confirmed
- Local anesthetic type, concentration, volume, total dose per side
- Additives used (dexamethasone, epinephrine)
- Sensory testing results
- Complications (if any)

**Anesthetic Management:**
- Induction agents and doses
- Maintenance technique (TIVA vs volatile)
- Adjunct infusions (dexmedetomidine, lidocaine, ketamine) with rates
- Hemodynamics (HR, BP trends)
- Fluids administered
- Estimated blood loss
- Emergence medications (reversal, antiemetics)
- Extubation time and condition

### PACU Note

**Handoff Elements:**
- Protocol used (Protocol 1: OFIA + PECS blocks)
- Block assessment (dermatomal coverage, functioning)
- Total opioids given intraoperatively (should be ZERO for Protocol 1)
- Adjunct infusions duration and total doses
- Emergence quality
- PACU orders (pain management, monitoring level)

**PACU Course:**
- Serial vital signs, RASS scores, pain scores
- Rescue medications administered
- Complications (PONV, excessive sedation, inadequate analgesia)
- Discharge readiness criteria met
- Disposition (home, monitored bed, ICU)

---

## Quality Metrics and Outcomes

### Expected Outcomes (Protocol 1 Benchmarks)

| Metric | Target | Comparison (Opioid-Based) |
|--------|--------|---------------------------|
| **PONV incidence** | 3-8% | 25-40% |
| **Mean PACU pain score** | 2-3/10 | 5-7/10 |
| **Intraoperative opioid use** | 0 mg | 100-200 mcg fentanyl equivalent |
| **PACU opioid rescue needed** | <20% patients | 60-80% patients |
| **Time to discharge readiness** | 60-90 min | 90-120 min |
| **Patient satisfaction** | ≥90% "satisfied" or "very satisfied" | 70-80% |

### Process Metrics to Track

**Block Success Rate:**
- Target: >90% of blocks provide adequate analgesia
- Audit monthly, review technique if <85%

**Protocol Adherence:**
- Multimodal medications given as specified
- Dexmedetomidine/lidocaine infusions used
- Zero intraoperative opioids maintained

**Complication Rates:**
- LAST events (target: 0%)
- Block-related complications (hematoma, infection, nerve injury): <1%
- Hemodynamic instability requiring intervention: <10%

### Continuous Quality Improvement

**Quarterly Review:**
- Aggregate data on outcomes
- Identify trends (increasing PONV, rescue opioid use)
- Adjust protocol if needed
- Share results with anesthesia department

**Case Review Triggers:**
- Any LAST event
- Block failure requiring rescue opioid >4 mg hydromorphone equivalent
- Severe PONV despite prophylaxis
- Unplanned ICU admission
- Patient complaint or dissatisfaction

---

## Evidence Base and References

### Key Guidelines

1. **ASRA Practice Advisory: Regional Anesthesia for Breast Surgery (2023)**
   - Recommends PECS blocks for breast procedures
   - Emphasizes multimodal analgesia and PONV prophylaxis

2. **ERAS Society Guidelines: Breast Reconstruction (2023-2024)**
   - Supports opioid-sparing techniques
   - Recommends regional anesthesia when feasible
   - Goal-directed fluid management

3. **ASRA Checklist for LAST Management (2020)**
   - Immediate lipid emulsion therapy
   - Modifications to ACLS

### Supporting Literature

**PECS Block Efficacy:**
- Multiple RCTs demonstrate superior analgesia vs no block
- Opioid consumption reduced 40-60%
- PONV incidence reduced
- Patient satisfaction improved

**Opioid-Free Anesthesia:**
- Growing evidence for breast surgery
- Comparable analgesia when multimodal optimized
- Enhanced recovery metrics
- Reduced side effects

**Dexmedetomidine in OFA:**
- Effective adjunct for breast procedures
- Reduces anesthetic requirements
- Smooth emergence
- Monitor for bradycardia/hypotension

**Ketamine Analgesia:**
- Sub-anesthetic doses (0.2-0.5 mg/kg) effective
- Reduces opioid needs
- Anti-hyperalgesic properties
- Minimal psychomimetic effects at analgesic doses

---

## Appendices

### Appendix A: PECS Block Ultrasound Anatomy Checklist

**Key Structures to Identify:**

| Structure | Ultrasound Appearance | Location |
|-----------|----------------------|----------|
| **Pectoralis major** | Thick, hypoechoic muscle | Superficial |
| **Pectoralis minor** | Thinner, deeper muscle | Deep to pec major |
| **Serratus anterior** | Finger-like projections on ribs | Lateral chest wall |
| **Ribs** | Hyperechoic with acoustic shadow | Deep landmarks |
| **Thoracoacromial artery** | Pulsatile vessel in PECS I plane | Color Doppler to identify |
| **Lateral thoracic artery** | May be visible in PECS II plane | Avoid injection into vessel |

**Probe Position:**
- Start at infraclavicular area
- Move laterally along 3rd-4th rib
- Parasagittal or slight oblique orientation

### Appendix B: Drug Compatibility Chart

**Syringe Admixture Compatibility (For Block Solution):**

| Combination | Compatible? | Notes |
|-------------|-------------|-------|
| **Ropivacaine + Dexamethasone** | Yes | Prolongs block 2-4 hours |
| **Bupivacaine + Dexamethasone** | Yes | Prolongs block 2-4 hours |
| **Ropivacaine + Epinephrine** | Yes | Standard 1:200,000-1:400,000 concentration |
| **Bupivacaine + Epinephrine** | Yes | Increases safe dose ceiling |
| **Dexamethasone + Epinephrine** | Yes | Can combine all three if desired |

**IV Infusion Compatibility:**

| Combination | Compatible? | Notes |
|-------------|-------------|-------|
| **Propofol + Dexmedetomidine** | No | Separate IV lines required |
| **Propofol + Lidocaine** | No | Separate lines |
| **Dexmedetomidine + Lidocaine** | Yes | Can Y-site together |

### Appendix C: Conversion Tables

**Opioid Equianalgesic Doses (Reference Only - Rescue Use):**

| Opioid | IV Dose | Conversion Factor |
|--------|---------|-------------------|
| **Morphine** | 10 mg | 1.0 |
| **Hydromorphone** | 1.5 mg | 6.7× morphine |
| **Fentanyl** | 100 mcg | 0.1× morphine |
| **Oxycodone** (PO) | 15 mg | 0.67× morphine |

**Example:** 0.4 mg hydromorphone IV ≈ 2.7 mg morphine IV ≈ 270 mcg fentanyl IV

### Appendix D: Local Anesthetic Maximum Dose Calculator

**Safe Dose Calculations:**

**Example Patient: 70 kg woman, bilateral PECS I + II**

**Using Ropivacaine 0.2% with epinephrine:**
- Maximum dose: 3 mg/kg = 210 mg for 70 kg patient
- Ropivacaine 0.2% = 2 mg/mL
- Total volume available: 210 mg ÷ 2 mg/mL = **105 mL maximum**
- Planned volume: 30-40 mL bilateral = 60-80 mL total = **120-160 mg** ✓ SAFE

**Using Bupivacaine 0.25% with epinephrine:**
- Maximum dose: 2.5 mg/kg = 175 mg for 70 kg patient
- Bupivacaine 0.25% = 2.5 mg/mL
- Total volume available: 175 mg ÷ 2.5 mg/mL = **70 mL maximum**
- Planned volume: 25-35 mL bilateral = 50-70 mL total = **125-175 mg** ✓ SAFE (at upper limit)

**Important:** Always calculate BEFORE drawing up local anesthetic.

---

## Version History

**Version 2.0 — December 2025**
- Complete clinical validation and safety review
- Corrected PECS block local anesthetic dosing (reduced to conservative concentrations)
- Added comprehensive emergence protocols
- Enhanced PACU management with phenotype-specific rescue protocols
- Added detailed safety considerations (LAST, dex adverse effects, ketamine)
- Expanded troubleshooting scenarios
- Added special population modifications
- Integrated monitoring requirements table
- Aligned with rTKA protocol framework structure
- Educational disclaimer added
- Evidence base and references updated

**Version 1.0 — December 2025**
- Initial protocol development

---

## Author and License

**Author:** Collin B. George, BS  
**Project Type:** Educational pre-medical protocol framework  
**Status:** Not validated for clinical use; requires institutional review

**License:** Creative Commons Attribution 4.0 International (CC BY 4.0)

**Acknowledgment:**  
This protocol synthesizes published literature on PECS blocks, opioid-free anesthesia, and ERAS principles. All clinical decisions require attending anesthesiologist judgment and patient-specific assessment.

---

**End of Protocol 1** — *Educational resource only. Adapt to institutional and attending preferences.*
